Precigen, Inc. (NASDAQ:PGEN) is one of the best multibagger penny stocks to buy according to analysts. On August 15, the ...

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

In a report released today, Jason Butler from Citizens JMP maintained a Buy rating on Precigen, with a price target of $8.00. The company’s shares closed today at $2.95. Take advantage of TipRanks ...

Precigen (PGEN) stock jumps as the FDA approves the company's gene therapy Papzimeos for adults with recurrent respiratory ...

In the last three months, Precigen Inc. (NASDAQ: PGEN) stock lost 23%. Here is what the fund said: "Precigen Inc. (PGEN) declined 30% following a strong gain in the fourth quarter of 2020.

Evaluating PGEN through my Dizzy lens, the unconditional FDA approval of PAPZIMEOS is a Tier-1 (Decisive) signal. Looking ahead to PAPZIMEOS’s launch, things will likely get moderately dizzy.

At Precigen, a filing with the SEC revealed that on Thursday, Randal J. Kirk bought 96,686 shares of PGEN, for a cost of $1.41 each, for a total investment of $136,327.

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Precigen, Inc. (NASDAQ:PGEN) stands against other hot biotech stocks under $5 ...